Durvalumab (Imfinzi®) is indicated for for the treatment of locally advanced, unresectable Non-small cell lung cancer (NSCLC)  in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)1.